Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling.
It is controversial whether monotherapy with immunotherapeutics is effective in early-stage hepatocellular carcinoma (HCC). We evaluated immunotherapy monotherapy as an initial neoadjuvant strategy. This prospective, single-arm, phase II trial of an adaptive neoadjuvant strategy
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.